NL300779I2 - Combinatie van a) olodaterol, het individuele optische R-isomeer daarvan, mengsels van individuele enantiomeren of racematen, zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, desgewenst in de vorm van solvaten en/of hydraten, en b) een tiotropiumzout; in het bijzonder combinatie van a) olodaterol en zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, en b) tiotropiumbromide, desgewenst in de vorm van een solvaat en/of hydraat; meer in het bijzonder combinatie van a) olodaterolhydrochloride en b) tiotropiumbromide, desgewenst in de vorm van het monohydraat - Google Patents
Combinatie van a) olodaterol, het individuele optische R-isomeer daarvan, mengsels van individuele enantiomeren of racematen, zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, desgewenst in de vorm van solvaten en/of hydraten, en b) een tiotropiumzout; in het bijzonder combinatie van a) olodaterol en zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, en b) tiotropiumbromide, desgewenst in de vorm van een solvaat en/of hydraat; meer in het bijzonder combinatie van a) olodaterolhydrochloride en b) tiotropiumbromide, desgewenst in de vorm van het monohydraatInfo
- Publication number
- NL300779I2 NL300779I2 NL300779C NL300779C NL300779I2 NL 300779 I2 NL300779 I2 NL 300779I2 NL 300779 C NL300779 C NL 300779C NL 300779 C NL300779 C NL 300779C NL 300779 I2 NL300779 I2 NL 300779I2
- Authority
- NL
- Netherlands
- Prior art keywords
- optionally
- olodaterol
- combination
- acid addition
- addition salts
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 4
- COUYJEVMBVSIHV-SFHVURJKSA-N olodaterol Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NC[C@H](O)C1=CC(O)=CC2=C1OCC(=O)N2 COUYJEVMBVSIHV-SFHVURJKSA-N 0.000 title 3
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 title 2
- 150000007513 acids Chemical class 0.000 title 2
- 229960004286 olodaterol Drugs 0.000 title 2
- 150000003839 salts Chemical class 0.000 title 2
- 239000012453 solvate Substances 0.000 title 2
- 229960000257 tiotropium bromide Drugs 0.000 title 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title 1
- 150000004677 hydrates Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000004682 monohydrates Chemical class 0.000 title 1
- 229960001733 olodaterol hydrochloride Drugs 0.000 title 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004019540A DE102004019540A1 (de) | 2004-04-22 | 2004-04-22 | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen |
| DE102004052987A DE102004052987A1 (de) | 2004-11-03 | 2004-11-03 | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen |
| EP05002496 | 2005-02-07 | ||
| EP05739576A EP1781298B1 (de) | 2004-04-22 | 2005-04-18 | Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen |
| PCT/EP2005/004073 WO2005102349A1 (de) | 2004-04-22 | 2005-04-18 | Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL300779I2 true NL300779I2 (nl) | 2017-11-02 |
Family
ID=34966478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL300779C NL300779I2 (nl) | 2004-04-22 | 2015-12-01 | Combinatie van a) olodaterol, het individuele optische R-isomeer daarvan, mengsels van individuele enantiomeren of racematen, zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, desgewenst in de vorm van solvaten en/of hydraten, en b) een tiotropiumzout; in het bijzonder combinatie van a) olodaterol en zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, en b) tiotropiumbromide, desgewenst in de vorm van een solvaat en/of hydraat; meer in het bijzonder combinatie van a) olodaterolhydrochloride en b) tiotropiumbromide, desgewenst in de vorm van het monohydraat |
Country Status (33)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| DE102004024452A1 (de) * | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die Inhalation von Betaagonisten |
| US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
| US7923455B2 (en) * | 2005-01-28 | 2011-04-12 | Boehringer Ingelheim International Gmbh | Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic |
| WO2006087316A1 (en) * | 2005-02-16 | 2006-08-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising anticholinergics and etiprednol |
| JP5270343B2 (ja) | 2005-08-15 | 2013-08-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベータミメティックスの製造方法 |
| US20070088030A1 (en) * | 2005-10-10 | 2007-04-19 | Barbara Niklaus-Humke | Aerosol formulations for the inhalation of beta-agonists |
| TWI396541B (zh) | 2005-10-10 | 2013-05-21 | Boehringer Ingelheim Int | 用於治療呼吸疾病之新穎藥物組合 |
| ATE529399T1 (de) | 2005-11-10 | 2011-11-15 | Nicholas S Bodor | Sanfte anticholinerge ester |
| WO2007093608A1 (de) * | 2006-02-16 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen |
| EP2051714B1 (de) * | 2006-08-07 | 2011-04-13 | Boehringer Ingelheim International GmbH | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen |
| UY30542A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de agonistas beta |
| UY30543A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de beta- agonistas |
| CA2667543A1 (en) * | 2006-10-26 | 2008-05-02 | Boehringer Ingelheim International Gmbh | New pharmaceutical combinations for treatment of respiratory and gastrointestinal disorders |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| CN101939316B (zh) | 2008-02-07 | 2013-10-02 | 贝林格尔.英格海姆国际有限公司 | 螺环杂环化合物、含有所述化合物的药物、其用途及其制备方法 |
| EP2313397B1 (de) | 2008-08-08 | 2016-04-20 | Boehringer Ingelheim International GmbH | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| US20120135969A1 (en) * | 2008-11-27 | 2012-05-31 | Boehringer Ingelheim International Gmbh | Novel powdered crystalline medicines for inhalation |
| WO2014016548A2 (en) | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
| JP2015533131A (ja) * | 2012-10-09 | 2015-11-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 咳を治療するためのベータ２−アドレナリン受容体作動薬 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4460581A (en) * | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
| US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
| FI88112C (fi) | 1985-07-30 | 1993-04-13 | Glaxo Group Ltd | Anordning foer administrering av laekemedel till patienter |
| SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
| SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| DE4318455A1 (de) | 1993-06-03 | 1994-12-08 | Boehringer Ingelheim Kg | Kapselhalterung |
| DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
| WO2001083462A1 (de) * | 2000-04-27 | 2001-11-08 | Boehringer Ingelheim Pharma Kg | Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| SI1326862T1 (sl) | 2000-10-12 | 2005-02-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Kristalinični monohidrat tiotropijevega bromida, postopek za njegovo pripravo in njegova uporaba za pripravo zdravila |
| KR100971616B1 (ko) | 2001-06-22 | 2010-07-22 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| DE10130371A1 (de) * | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
| ES2203327B1 (es) * | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| DE10230751A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern |
| DE10246374A1 (de) * | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
-
2005
- 2005-04-18 AT AT05739576T patent/ATE539754T1/de active
- 2005-04-18 AU AU2005235419A patent/AU2005235419B2/en active Active
- 2005-04-18 DK DK05739576.6T patent/DK1781298T3/da active
- 2005-04-18 PL PL11187038T patent/PL2422786T3/pl unknown
- 2005-04-18 PT PT111870382T patent/PT2422786E/pt unknown
- 2005-04-18 SG SG200902525-5A patent/SG152237A1/en unknown
- 2005-04-18 CA CA2559699A patent/CA2559699C/en not_active Expired - Fee Related
- 2005-04-18 EP EP11187038.2A patent/EP2422786B1/de not_active Expired - Lifetime
- 2005-04-18 SI SI200531488T patent/SI1781298T1/sl unknown
- 2005-04-18 EP EP05739576A patent/EP1781298B1/de not_active Expired - Lifetime
- 2005-04-18 KR KR1020137011141A patent/KR20130049840A/ko not_active Ceased
- 2005-04-18 PL PL05739576T patent/PL1781298T4/pl unknown
- 2005-04-18 BR BRPI0510080A patent/BRPI0510080B8/pt active IP Right Grant
- 2005-04-18 EA EA200601846A patent/EA013157B1/ru active Protection Beyond IP Right Term
- 2005-04-18 JP JP2007508805A patent/JP2007533683A/ja active Pending
- 2005-04-18 NZ NZ550797A patent/NZ550797A/en not_active IP Right Cessation
- 2005-04-18 ES ES05739576T patent/ES2380370T3/es not_active Expired - Lifetime
- 2005-04-18 WO PCT/EP2005/004073 patent/WO2005102349A1/de not_active Ceased
- 2005-04-18 SI SI200531904T patent/SI2422786T1/sl unknown
- 2005-04-18 PT PT05739576T patent/PT1781298E/pt unknown
- 2005-04-18 KR KR1020067024528A patent/KR101287460B1/ko not_active Expired - Lifetime
- 2005-04-18 ES ES11187038.2T patent/ES2523518T3/es not_active Expired - Lifetime
- 2005-04-18 DK DK11187038.2T patent/DK2422786T3/da active
- 2005-04-19 UY UY28861A patent/UY28861A1/es not_active Application Discontinuation
- 2005-04-20 MY MYPI20051739A patent/MY148945A/en unknown
- 2005-04-20 PE PE2005000432A patent/PE20060462A1/es active IP Right Grant
- 2005-04-21 TW TW094112735A patent/TWI372056B/zh active
- 2005-04-21 TW TW101108945A patent/TWI374739B/zh not_active IP Right Cessation
- 2005-04-22 AR ARP050101601A patent/AR049262A1/es not_active Application Discontinuation
-
2006
- 2006-08-08 ZA ZA2006/06624A patent/ZA200606624B/en unknown
- 2006-08-24 IL IL177685A patent/IL177685A/en active IP Right Grant
- 2006-10-23 EC EC2006006947A patent/ECSP066947A/es unknown
- 2006-11-02 NO NO20065060A patent/NO337714B1/no active Protection Beyond IP Right Term
-
2012
- 2012-03-26 CY CY20121100308T patent/CY1113890T1/el unknown
-
2013
- 2013-05-26 IL IL226562A patent/IL226562A0/en unknown
-
2014
- 2014-11-07 CY CY20141100925T patent/CY1115719T1/el unknown
-
2015
- 2015-12-01 BE BE2015C065C patent/BE2015C065I2/fr unknown
- 2015-12-01 NL NL300779C patent/NL300779I2/nl unknown
- 2015-12-01 HU HUS1500058C patent/HUS1500058I1/hu unknown
- 2015-12-01 LT LTPA2015043C patent/LTC1781298I2/lt unknown
-
2016
- 2016-05-09 LU LU93066C patent/LU93066I2/fr unknown
- 2016-06-22 FR FR16C0029C patent/FR16C0029I2/fr active Active
- 2016-12-01 NO NO2016022C patent/NO2016022I1/no unknown
-
2017
- 2017-01-13 FI FIC20170005C patent/FIC20170005I1/fi unknown
- 2017-04-20 CY CY2017014C patent/CY2017014I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL300779I2 (nl) | Combinatie van a) olodaterol, het individuele optische R-isomeer daarvan, mengsels van individuele enantiomeren of racematen, zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, desgewenst in de vorm van solvaten en/of hydraten, en b) een tiotropiumzout; in het bijzonder combinatie van a) olodaterol en zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, en b) tiotropiumbromide, desgewenst in de vorm van een solvaat en/of hydraat; meer in het bijzonder combinatie van a) olodaterolhydrochloride en b) tiotropiumbromide, desgewenst in de vorm van het monohydraat | |
| NL301104I1 (nl) | Fedratinib, of een farmaceutisch aanvaardbaar zout daarvan, of een farmaceutisch aanvaardbaar hydraat daarvan, in het bijzonder fedratinibdihydrochloridemonohydraat | |
| NO2017010I2 (no) | Dolutegravir eller et farmasøytisk akseptabelt salt eller solvat derav | |
| NL300974I2 (nl) | Binimetinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat | |
| NO2022057I1 (no) | Capmatinib or a pharmaceutically acceptable salt thereof | |
| NL301150I2 (nl) | setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301042I2 (nl) | Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301049I1 (nl) | Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NO2020038I1 (no) | Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt | |
| DK1711481T4 (da) | Krystallinsk monohydrat som kinaseinhibitorer | |
| NL300913I2 (nl) | Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride | |
| NO2018028I1 (no) | Alogliptin i kombinasjon med plaglitazon, hver eventuelt i form av et farmasøytisk akseptabelt salt derav | |
| NL300640I2 (nl) | Alogliptine of een farmaceutisch aanvaardbaar zout daarvan | |
| NL300937I2 (nl) | Niraparib, of een tautomeer daarvan, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder het tosylaat of een hydraat, meer in het bijzonder het tosylaat monohydraat | |
| IL190198A0 (en) | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | |
| SMP201000002B (it) | Sali dell'inibitore di chinasi janus (R)-3-(4-(7H-pirrolo[2,3-D]pirimidin-4-IL)-1H-pirazoli-1-IL)-3-ciclopentilpropanonitrile | |
| AR061980A1 (es) | Acilanilidas sustituidas y metodos para su utilizacion | |
| ME02688B (me) | Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta | |
| TW200716567A (en) | Aspartyl protease inhibitors | |
| DK1789021T3 (da) | Forlænget-frigivelse-tabletformulering indeholdende pramipexol eller et farmaceutisk acceptabelt salt deraf | |
| ZA200801351B (en) | Sulphonypyrrole hydrochloride salts as histone deacetylases inhibitors | |
| ZA200708811B (en) | Use of a sulfonamide compound for improving the pharma-cokinetics of a drug | |
| IL177101A0 (en) | Quinoline derivatives for use as mycobacterial inhibitors | |
| DK2011796T3 (da) | Neurogenese-inducer eller terapeutisk middel mod neuropati omfattende alkyletherderivat eller salt deraf | |
| ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren |